| Tiffiny Ann Overath, | |
|
283 Twin Lakes Rd, Melbourne, FL 32901-8658 | |
| (319) 331-4502 | |
| Not Available |
| Full Name | Tiffiny Ann Overath |
|---|---|
| Gender | Female |
| Speciality | Counselor - Mental Health |
| Location | 283 Twin Lakes Rd, Melbourne, Florida |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043919483 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | SW18847 (Florida) | Primary |
| Entity Name | Counseling Resource Services, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164819041 PECOS PAC ID: 3779884093 Enrollment ID: O20151210001645 |
News Archive
University of California, Berkeley, scientists have found a way to overcome one of the main limitations of ultrasound imaging the poor resolution of the picture.
In the Senate, a "voteless" markup was held on Budget Committee Chairman Kent Conrad's, D-N.D., presentation of the Bowles-Simpson plan. Meanwhile, Sen. Pat Toomey, R-Pa., says he will bring the House GOP budget plan advanced by Rep. Paul Ryan, R-Wis., up for a vote by the full Senate later this year.
Idera Pharmaceuticals, Inc., today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon Merck KGaA's initiation of a Phase 1b clinical trial of IMO-2055 (EMD 1201081), an agonist of Toll-like Receptor 9 (TLR9), in combination with cisplatin, fluorouracil and cetuximab (Erbitux®) in first-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN).
The results are now published in Nature Medicine and at the same time the tool - the Molecular Tumor Board Portal - will be launched on www.mtbp.org. Janne Lehtiö, professor at the Karolinska Institutet Department of Oncology-Pathology led this work, along with researcher David Tamborero.
Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the United Kingdom's National Institute for Health and Clinical Excellence (NICE) has issued final draft guidance indicating that ILUVIEN is not recommended for the treatment of chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tiffiny Ann Overath, 283 Twin Lakes Rd, Melbourne, FL 32901-8658 Ph: (319) 331-4502 | Tiffiny Ann Overath, 283 Twin Lakes Rd, Melbourne, FL 32901-8658 Ph: (319) 331-4502 |
News Archive
University of California, Berkeley, scientists have found a way to overcome one of the main limitations of ultrasound imaging the poor resolution of the picture.
In the Senate, a "voteless" markup was held on Budget Committee Chairman Kent Conrad's, D-N.D., presentation of the Bowles-Simpson plan. Meanwhile, Sen. Pat Toomey, R-Pa., says he will bring the House GOP budget plan advanced by Rep. Paul Ryan, R-Wis., up for a vote by the full Senate later this year.
Idera Pharmaceuticals, Inc., today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon Merck KGaA's initiation of a Phase 1b clinical trial of IMO-2055 (EMD 1201081), an agonist of Toll-like Receptor 9 (TLR9), in combination with cisplatin, fluorouracil and cetuximab (Erbitux®) in first-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN).
The results are now published in Nature Medicine and at the same time the tool - the Molecular Tumor Board Portal - will be launched on www.mtbp.org. Janne Lehtiö, professor at the Karolinska Institutet Department of Oncology-Pathology led this work, along with researcher David Tamborero.
Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the United Kingdom's National Institute for Health and Clinical Excellence (NICE) has issued final draft guidance indicating that ILUVIEN is not recommended for the treatment of chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
› Verified 6 days ago
Michelle Cannon, MSW Counselor Medicare: Not Enrolled in Medicare Practice Location: 326 Croton Rd, Melbourne, FL 32935 Phone: 321-752-3170 Fax: 321-752-3179 | |
Bryanna Oswalt, Counselor Medicare: Not Enrolled in Medicare Practice Location: 4450 W Eau Gallie Blvd, Suite 200, Melbourne, FL 32934 Phone: 321-726-2860 | |
Mrs. Jennifer Lovell, MA Counselor Medicare: Not Enrolled in Medicare Practice Location: 3345 Delaney Dr Apt 101, Melbourne, FL 32934 Phone: 321-557-1888 | |
Angela Bryan, Counselor Medicare: Not Enrolled in Medicare Practice Location: 3270 Suntree Blvd Ste 103a, Melbourne, FL 32940 Phone: 321-757-4015 | |
Ms. J. Phyllis Brannen, LCSW, CAP Counselor Medicare: Medicare Enrolled Practice Location: 1503 Pine St, Melbourne, FL 32901 Phone: 321-953-3225 Fax: 321-953-3252 | |
Anne Wolfram, LMHC Counselor Medicare: Not Enrolled in Medicare Practice Location: 3040 N Wickham Rd, Suite 3, Melbourne, FL 32935 Phone: 321-254-3042 Fax: 321-254-4770 | |
Mrs. Kwanya Toussaint, LMHC Counselor Medicare: Not Enrolled in Medicare Practice Location: 3270 Suntree Blvd Ste 127, Melbourne, FL 32940 Phone: 321-610-7949 Fax: 321-610-7947 |